Jennifer Lin
Director, Early Development & In Process Analytics GSK
Jennifer Lin is Director of Early CMC Development and In-Process Analytics at GSK.
She previously held roles at Beam Therapeutics, leading preclinical development and manufacturing for plasmid, mRNA, and LNP platforms. Earlier in her career, she worked at Biogen in gene therapy and at Pfizer as a Senior Scientist. Jennifer holds a Ph.D. in Microbiology from the University of Massachusetts Amherst.
Seminars
Thursday 1st October 2026
Advancing Multi-Attribute Analytical Strategies to Accelerate mRNA Process Development & Product Quality Control
4:30 pm
- Exploring how multi-attribute analytical approaches can consolidate identity, purity, integrity & dsRNA assessment into streamlined, data-rich workflows for mRNA development
- Evaluating emerging technologies including sequencing-based and chromatographic assays to improve process understanding while reducing analytical complexity and turnaround time
- Discussing how sensitive, high-throughput analytical platforms can support faster platform development, enhanced product quality & accelerated progression from discovery to IND-enabling studies
